Table 1.

Comparison of criteria used to evaluate therapy in metastatic renal cell carcinoma

Criteria	Measurements	Definition of response	Definition of progression
RECIST [2]	Sum of largest diameter (SLD) of target lesions	Decrease of SLD of more than –30% compared to baseline	Increase of SLD of more than +20% compared to nadir
RECIST modified threshold	Sum of largest diameter (SLD) of target lesions	Decrease of SLD of more than –10% compared to baseline	Identical to RECIST
Choi [21]	Sum of largest diameter (SLD) and mean attenuation of target lesions	Decrease of SLD of more than –10% compared to baseline OR Decrease of mean attenuation of more than –15% compared to baseline	Not specifically evaluated in publications
Modified Choi [25]	Sum of largest diameter (SLD) and mean attenuation of target lesions	Decrease of SLD of more than –10% compared to baseline AND Decrease of mean attenuation of more than –15% compared to baseline	Not specifically evaluated in publications
iRECIST [7]	Sum of largest diameter (SLD) and mean attenuation of target lesions	Identical to RECIST May occur after an unconfirmed progression	Progression must be confirmed on follow-up imaging